European Association of Nuclear Medicine: At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223- dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients.
Latest from John Shanahan
- Medical isotopes (M. Alex Brown) USofA
- Wind and solar energy in Germany (P Gosselin, H W Sinn) Germany
- Albert Einstein quotes Switzerland USofA
- Environmentalists for Nuclear - USA Newsletter, 2018 1 (John Shanahan) USofA
- Greenpeace sucht vergeblich nach dem Klimawandel (Sebastian Luening, Kalte Sonne) Germany German Deutsch